GLASGOW, Scotland – A single infusion of zoledronic acid (Aclasta) prevents bone turnover in people at risk of Paget’s disease in an analysis of data from the Zoledronate in the Prevention of Paget’s ...
The efficacy of zoledronic acid after hip fracture was evaluated in 2,127 patients (1,619 women and 508 men) aged 50 years and older (N Engl J Med. 2007;357:1799-1809). The Health Outcomes and Reduced ...
Bisphosphonate therapy should continue as long as the patient is able to tolerate therapy or until evidence of a substantial decline in performance status. A serum creatinine measurement should be ...
Medicare covers the injectable drug, Reclast, when a doctor deems it medically necessary for the treatment and prevention of osteoporosis. There are specific eligibility criteria, including having ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback